Atea Pharmaceuticals Inc. (AVIR) – Management Comments
-
Atea Pharmaceuticals Inc. (AVIR) Outlines 2022 Strategic Priorities
-
Atea Pharmaceuticals Inc. (AVIR) Reports First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19
-
-
-
-
-
-
-
-
Back to AVIR Stock Lookup